Compare iShares Core Growth Allocation ETF (AOR) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core Growth Allocation ETF vs Stryker Corporation — how do they compare? iShares Core Growth Allocation ETF trades at $70.12, while Stryker Corporation trades at $341.64 (market cap $133.54B). The key difference: Stryker Corporation pays a 1.01% dividend while iShares Core Growth Allocation ETF pays none, and iShares Core Growth Allocation ETF is trading nearer its 52-week high, Stryker Corporation nearer its low. Which is the better fit depends on your goals.
| AOR | SYK | |
|---|---|---|
52-Week High | $70.12 | $394.34 |
52-Week Low | $62.26 | $282.58 |
Market Cap | — | $133.54B |
Sector | — | Technology |
Enterprise Value | — | $145.01B |
Dividend Yield | — | 1.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AOR, the iShares Core Growth Allocation ETF, trades at $69.87, showing minimal daily movement. Technical indicators are bullish based on moving averages, though the RSI suggests potential overbought conditions. The fund maintains a fixed 60/40 stock/bond allocation, offering a low-cost, diversified core holding strategy with a 20 basis point fee.
The outlook for AOR is stable, providing a straightforward asset allocation tool for long-term investors. Key risks include underperformance versus pure equity indices like the S&P 500 over extended periods, as noted by financial media, and sensitivity to interest rate changes affecting the bond portion.
Stryker (SYK) trades at $341.17, down 1.34% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $379.44. The company reported strong Q2 2026 results with a 9% organic sales growth and an EPS beat, recovering from a Q1 cyber incident. Profitability remains robust with a net income margin of 14.43% and a dividend yield supported by recent increases.
The stock offers upside potential driven by earnings momentum and product innovation like Mako RPS, but risks include competitive pressures and past cybersecurity disruptions. Analyst sentiment is strongly bullish with 74% buy ratings, though valuation multiples like a P/E of 36.08 suggest premium pricing relative to historical norms.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core Growth Allocation ETF
The fund is a fund of funds and seeks its investment objective by investing primarily in underlying funds that themselves seek investment results corresponding to their own respective underlying indexes. It generally will invest at least 80% of its assets in the component securities of its underlying index. The index measures the performance of the S&P Dow Jones Indices LLC proprietary allocation model.
Read more on AOR →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
